Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated ...

Topics: Corporate, Business, Drug design and discovery Read More

Aptuit Announces Expansion of Compound Library

Part of 5m$ Investment in Integrated Drug Discovery Capabilities Greenwich, CT, November 30, 2016 - Aptuit, LLC today announced that it had successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to ...

Topics: Corporate, Business Read More

Aptuit names Peter Gray as the new Chairman of Aptuit Holdings, LLC

Greenwich, CT, November 28, 2016 – Aptuit today announced that Peter Gray has been appointed Chairman of Aptuit’s Board of Managers. Mr. Gray assumes the role of Chairman having previously served as Non-Executive Director since March 2015. Mr. Gray said, “I am honoured to assume the role of ...

Topics: Corporate Read More

Aptuit announces enhancement of integrated IND enabling services

Expanding capabilities and capacity in formulation development and safety assessment Greenwich, CT, October 13, 2016 - Aptuit, LLC today announced that it has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to ...

Topics: Business Read More

Tim Tyson to leave as Chairman of Aptuit

Tim Tyson has resigned as Chairman to focus on other opportunities.  The company wishes him well for the future and thanks him for his many contributions.

Aptuit LLC and Dimension Therapeutics enter strategic partnership to advance select Dimension programs toward IND filing

Aptuit Greenwich, CT, and Cambridge, MA - July 7, 2016 – Aptuit LLC, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, ...

Topics: Strategy, Corporate, Business Read More

Henning Steinhagen appointed as Executive Vice President Drug Discovery and Development and Site-Head Verona

We are pleased to announce the appointment of Henning Steinhagen, PhD, as Executive Vice President Drug Discovery and Development, and Site-Head Verona, completing Aptuit’s executive leadership team.

Topics: New appointments Read More

Aptuit obtains renewal of French CIR tax accreditation

Good news for our French customers! We have renewed our French CIR tax accreditation for 2016-2018. So you will continue to benefit from 20-30% tax relief when you use our services. “The renewal of the CIR accreditation for an additional three-year period will provide additional tangible benefits ...

Topics: Finance Read More

Aptuit announces acquisition of Kuecept Ltd

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services Greenwich, CT, May, 10th, 2016 - Aptuit, LLC today announced that it has acquired Kuecept Ltd to meet strong customer demand for specialist drug ...

Topics: Business, Acquisition Read More

Iain Rusling, Appointed VP of Quality Management and EHS

We are pleased to announce the appointment of Iain Rusling as Vice President of Quality Management and EHS. Iain joins us directly from Sandoz, where he was Head of Third Party QA, Europe/META. In this role he led all quality aspects for over 350 third party contract manufacturers in Western Europe ...

Topics: New appointments Read More